HDAC9 and thyroid gland undifferentiated (anaplastic) carcinoma: In this study, we investigated the possible use of SAHA, an HDAC inhibitor, and PJ34, a PARP inhibitor, in combination, in a cellular model of anaplastic thyroid cancer.